Shawn Moaddeb - Chairman

Founder & Chairman of Adventus Ventures Corp., a medical technology incubator. Shawn is an entrepreneur with a strong background in both start-up and large established organizations (Johnson & Johnson, St. Jude Medical).

Shawn has held various leadership positions; CEO, senior executive, and board member. Shawn has co-founded multiple medical device companies with several successful exists: EP Dynamics, Lavita Technologies, Renal Dynamics, Vessix Vascular, Ellipse Technologies, Savona Therapeutics, and Oncogenics Guidance Systems. 

Shawn is currently Chairman of the board of Pressao Medical  and Chairman of  the board of Vascular Health and CEO & Chairman of the board of Allevion Therapeutics.

Joel S. Marcus, JD, CPA, is Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE: ARE), a real estate investment trust (REIT) that pioneered life science real estate and transformed it from a specialty niche to a mainstream asset class. Alexandria is the preeminent, largest, and longest-tenured owner, operator, and developer uniquely focused on collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations. Since co-founding the company in 1994 with a $19 million Series A, Mr. Marcus has led its remarkable growth into an S&P 500 company that has become the leading REIT focused on the life science industry, with a total market capitalization of $29 billion, an operating asset base in North America of approximately 40 million RSF, and a long-term total shareholder return of 1,199% as of December 31, 2024. 

Mr. Marcus also leads Alexandria Venture Investments, the company’s strategic venture capital platform, which he founded in 1996. Some of his most notable early-stage investments include Alnylam Pharmaceuticals, Google, Intra-Cellular Therapies, and Moderna. With approximately $1.5 billion under management, Alexandria Venture Investments actively invests in disruptive life science companies that are advancing transformative new modalities, platforms, and innovative medicines to meaningfully improve human health. Mr. Marcus introduced Alexandria’s thought leadership vertical in 2011 when he co-founded the renowned Alexandria Summit®, a highly collaborative, neutral platform that explores important issues facing human health and leverages its powerful collective voice to foster impactful collaborations and shape policy.

Mr. Marcus also leads Alexandria’s corporate responsibility initiatives, which aim to address some of the nation’s most urgent challenges, including mental health and addiction. To reverse the trajectory of the opioid epidemic, Alexandria partnered with Verily, an Alphabet company, to pioneer OneFifteen, a one-of-a-kind full continuum of care model to treat addiction. 

Mr. Marcus serves on the boards of several biotechnology companies and non-profits, including the 9/11 Memorial & Museum, Emily Krzyzewski Center, National Medal of Honor Museum, Navy SEAL Foundation, Office of Strategic Services Society, and TOPGUN Association. He served on the board of directors of Intra-Cellular Therapies, Inc. from 2006 until its acquisition by Johnson & Johnson in 2025.

Mr. Marcus received his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.

Hakon Bergheim joined Anaxiom Corporation in March of 2025 as the President and Chief Executive Officer. 

Hakon has over 15 years of experience within medical devices in both start-up and publicly traded companies. Prior to joining Anaxiom Hakon was the Chief Operating Officer at Adagio Medical, a leading innovator in the treatment of cardiac arrhythmias. 

Hakon holds a Bachelor of Science in Chemical Engineering from the University of California Irvine and Masters of Business Administration from the University of Southern California. 

Dr. Reynolds Delgado works in Houston, TX as a Cardiologist and is a leader in the field of heart failure.  He is a member of Texas Heart Institute and is on staff at Baylor St. Luke’s Medical Center. 

Dr. Delgado is board certified in Advanced Heart Failure and Transplant Cardiology and graduated from University of Texas Southwestern Medical Center.  He completed residency at University of Texas Southwestern Medical Center and fellowship at Texas Heart Institute. 

Dr. Delgado is a Medical Director of Mechanical Support Devices in Heart Failure at Texas Heart Institute and has been on various advisory boards as well as being principal investigator on several clinical studies.  In addition, he has authored articles in the New England Journal of Medicine that led to FDA approval of the Heartmate II™ LVAD.

In addition to being a Founder and board member of Anaxiom, Dr. Delgado is a co-founder and President of the Houston Heart Failure Society and a long-standing research collaborator with NASA Johnson Space Center’s human space flight physiology laboratory.  He is also the founder of Procyrion, Inc.

Olav is the Founder and Managing Director of Fjord Ventures LLC, a life sciences accelerator company whose portfolio includes Adagio Medical, Inc.; Anaxiom Corporation; Kato Pharmaceuticals, Inc.; Prelude Corporation; Sonendo, Inc.; and YAP Therapeutics, Inc. Each of these companies was founded by Olav.

Previously, Olav was General Partner of Domain Associates, which he joined in 1995 and was charged with forming and providing active management to new life sciences companies. There he established the Company Creation Initiative that led to the formation of several companies, including VenPro; 3F Therapeutics (acquired by Medtronic); Vessix Vascular (acquired by Boston Scientific); Volcano Therapeutics (acquired by Phillips); and Glaukos Corporation.

Earlier, Olav spent 18 years in general management positions at Baxter Healthcare Corporation, serving as Corporate Group Vice President and also President of Baxter’s Cardiovascular Group (now: Edwards LifeSciences). His prior positions with Baxter included President of Immunotherapy Worldwide, President BioTech Europe, and President of Baxter in Germany and General Manager of the Nordic area.